42086-64-6

Basic information

• Product Name: Cyclopentanol, 2-phenyl-, (1R,2S)-rel-
• CAS NO: 42086-64-6
• Molecular Formula: C11H14O
• Molecular Weight: 162.232
• Mol File: 42086-64-6.mol

Chemical Properties

• CAS DataBase Reference: Cyclopentanol, 2-phenyl-, (1R,2S)-rel-(CAS DataBase Reference)
• NIST Chemistry Reference: Cyclopentanol, 2-phenyl-, (1R,2S)-rel-(42086-64-6)
• EPA Substance Registry System: Cyclopentanol, 2-phenyl-, (1R,2S)-rel-(42086-64-6)

Safety Data

• Hazardous Substances Data: 42086-64-6(Hazardous Substances Data)

Upstream product

• 98-88-4 benzoyl chloride 
• 108-05-4 vinyl acetate 
• 2362-73-4 (+/-)-cis-2-phenylcyclopentanol 
• 285-67-6 Cyclopentene oxide 
• 591-51-5 phenyllithium 
• 6226-35-3 (2-Cyclopropyl-2-phenyl-ethyl)-tosylat 
• 825-54-7 cyclopent-1-en-1-ylbenzene 
• 96-09-3 styrene oxide 
• 100-58-3 phenylmagnesium bromide 
• 1198-34-1 2-Phenylcyclopentanone 
• 108-86-1 bromobenzene 
• 10487-96-4 1-phenylcyclopentanol 
• 120-92-3 cyclopentanone 
• 152293-92-0 tert-Butyl-((E)-5-chloro-2-phenyl-pent-3-enyloxy)-dimethyl-silane 

Downstream Products

• 38805-89-9 (1S,2R)-2-phenylcyclopentanol 
• 135356-98-8 (1R,2S)-2-phenylcyclopentyl acetate 
• 135357-04-9 Acetic acid (1S,2R)-2-phenyl-cyclopentyl ester 
• 2362-73-4 (1R,2R)-(-)-cis-2-Phenylcyclopentanol 
• 2362-73-4 (+/-)-cis-2-phenylcyclopentanol 
• 2371-92-8 trans-1-Phenyl-2-<4-toluolsulfonyloxy>-cyclopentan 
• 38805-83-3 (+)-trans-2-Phenylcyclopentyl-phthalat 
• 1015249-06-5 C₁₄H₁₈O₂ 
• 1198-34-1 2-Phenylcyclopentanone 
• 38805-90-2 (1R,2S)‐2‐phenylcyclopentanol 
• 676552-21-9 (1R,2R)-2-phenylcyclopentyl acetate 

Relevant articles and documents

Diversity-Oriented Synthesis of Bioactive Azaspirocycles

A collection of novel azaspirocyclic β-arylethylamines was prepared in good yield and excellent diastereoselectivity by an expedient strategy that features condensation of a cyclic ketone with an amino allylsilane and a tandem aza-Sakurai cyclization to generate several different spirocyclic N-heterocycles. Subsequent elaboration of the spirocyclic scaffold was achieved via Pictet-Spengler cyclizations, Suzuki cross-coupling reactions, N-functionalizations, and olefin refunctionalization reactions to create a diverse library of compounds, several of which have nanomolar affinity for the sigma 1 receptor and transmembrane protein 97 (TMEM97).

Visible-Light-Mediated Aerobic Oxidation of Organoboron Compounds Using in Situ Generated Hydrogen Peroxide

A simple and general visible-light-mediated oxidation of organoboron compounds has been developed with rose bengal as the photocatalyst, substoichiometric Et3N as the electron donor, as well as air as the oxidant. This mild and metal-free protocol shows a broad substrate scope and provides a wide range of aliphatic alcohols and phenols in moderate to excellent yields. Notably, the robustness of this method is demonstrated on the stereospecific aerobic oxidation of organoboron compounds.

(Poly)cationic λ3-Iodane-Mediated Oxidative Ring Expansion of Secondary Alcohols

Herein, a simplified approach to the synthesis of medium-ring ethers through the electrophilic activation of secondary alcohols with (poly)cationic λ3-iodanes (N-HVIs) is reported. Excellent levels of selectivity are achieved for C–O bond migration over established α-elimination pathways, enabled by the unique reactivity of a novel 2-OMe-pyridine-ligated N-HVI. The resulting hexafluoroisopropanol (HFIP) acetals are readily derivatized with a range of nucleophiles, providing a versatile functional handle for subsequent manipulations. The utility of this methodology for late-stage natural product derivatization was also demonstrated, providing a new tool for diversity-oriented synthesis and complexity-to-diversity (CTD) efforts. Preliminary mechanistic investigations reveal a strong effect of alcohol conformation on the reactive pathway, thus providing a predictive power in the application of this approach to complex molecule synthesis.

Asymmetric Induction via a Helically Chiral Anion: Enantioselective Pentacarboxycyclopentadiene Br?nsted Acid-Catalyzed Inverse-Electron-Demand Diels-Alder Cycloaddition of Oxocarbenium Ions

An enantioselective catalytic inverse-electron-demand Diels-Alder reaction of salicylaldehyde acetal-derived oxocarbenium ions and vinyl ethers to generate 2,4-dioxychromanes is described. Chiral pentacarboxycyclopentadiene (PCCP) acids are found to be effective for a variety of substrates. Computational and X-ray crystallographic analyses support the unique hypothesis that an anion with point-chirality-induced helical chirality dictates the absolute sense of stereochemistry in this reaction.

Enantioselective Hydroazidation of Trisubstituted Non-Activated Alkenes

A one-pot procedure for the enantioselective hydroazidation of non-activated trisubstituted alkenes is described. Hydroboration with monoisopinocampheylborane (IpcBH2) provides dialkylboranes that are in situ selectively converted into monoalkyl-substituted catecholboranes; these undergo radical azidation upon treatment with benzenesulfonyl azide and a radical initiator. Enantiomerically enriched azides were thus obtained in yields of 59–81 % and enantioselectivities of up to 94:6 e.r. (98:2 e.r. if the intermediate dialkylborane is purified by crystallization). A rapid access to enantiomerically pure (+)-rodocaine is also described. The use of other arenesulfonyl radical traps enables enantioselective hydroallylation, hydrosulfanylation, and hydrobromination reactions with yields of 71–86 %.

ERK INHIBITORS

The present invention provides a compound of Formula (I) or the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are ERK2 inhibitors. The invention also provides a pharmaceutical composition comprising an effective amount of at least one compound of Formula (I) and a pharmaceutically acceptable carrier. The invention also provides a pharmaceutical composition comprising an effective amount of at least one compound of Formula (I) and an effective amount of at least one other pharmaceutically active ingredient (such as, for example, a chemotherapeutic agent), and a pharmaceutically acceptable carrier.

Kinetic resolution of secondary alcohols catalyzed by chiral phosphoric acids

Acid instead of base: Kinetic resolution of secondary alcohols is realized using chiral Bronsted acid catalyzed acylation instead of the conventional basic conditions. A broad range of functional groups are tolerated, such as aldehydes, carboxylic acids, and enoates. The selectivity factor (s) reaches up to 215 at ambient temperature. Copyright

Discovery of novel, potent, and selective inhibitors of 3-phosphoinositide-dependent kinase (PDK1)

Analogues substituted with various amines at the 6-position of the pyrazine ring on (4-amino-7-isopropyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)pyrazin-2- ylmethanone were discovered as potent and selective inhibitors of PDK1 with potential as anticancer agents. An early lead with 2-pyridine-3-ylethylamine as the pyrazine substituent showed moderate potency and selectivity. Structure-based drug design led to improved potency and selectivity against PI3Kα through a combination of cyclizing the ethylene spacer into a saturated, five-membered ring and substituting on the 4-position of the aryl ring with a fluorine. ADME properties were improved by lowering the lipophilicity with heteroatom replacements in the saturated, five-membered ring. The optimized analogues have a PDK1 Ki of 1 nM and >100-fold selectivity against PI3K/AKT-pathway kinases. The cellular potency of these analogues was assessed by the inhibition of AKT phosphorylation (T308) and by their antiproliferation activity against a number of tumor cell lines. (Figure presented)

Kinetic resolution of (±)-trans- and (±)-cis-2- phenylcyclopentanamine by CALB-catalyzed aminolysis of esters: The key role of the leaving group

Kinetic resolution of (±)-trans- and (±)-cis-2- phenylcyclopentanamine is effectively performed by lipase B from Candida antarctica, (CALB)-catalyzed aminolysis reaction. Whereas reaction between (±)-trans-2-phenylcyclopentanamine and ethyl acetate proceeds with a very high E value (>200) and conversion (50%), the corresponding acetylation of (±)-cis-2-phenylcyclopentanamine happens with low E value (16) and conversion (28%). Nevertheless, this problem is overcome using other acyl donors such as (±)-1-phenylethyl and (±)-cis-2-phenylcyclopentyl methoxyacetates. The influence of the acyl donor on the CALB-catalyzed aminolysis of (±)-cis-2-phenylcyclopentanamine is also studied.

Cyclopentyl sulfonamide derivatives

The present invention provides certain cyclopentyl sulfonamide derivatives of formula (I): useful for potentiating glutamate receptor function in a mammal. It also relates to novel cyclopentyl sulfonamide derivatives, to processes for their preparation and to pharmaceutical compositions containing them.